Diabetes mellitus increases the risk of hospital mortality in patients with Covid-19

Systematic review with meta-analysis

Larry E. Miller, PhD, PStat*, Ruemon Bhattacharyya, Anna L. Miller

Abstract

Background: The mortality rate associated with Covid-19 varies considerably among studies and determinants of this variability are not well characterized.

Methods: A systematic review of peer-reviewed literature published through March 31, 2020 was performed to estimate the mortality rate among hospitalized patients in China with a confirmed diagnosis of Covid-19. Hospital mortality rates were estimated using an inverse variance-weighted random-effects meta-analysis model. Funnel plot symmetry was evaluated for small-study effects, a one-study removed sensitivity analysis assessed the influence of individual studies on the pooled mortality rate, and metaregression assessed the association of potential confounding variables with mortality rates.

Results: The review included 16 observational studies involving 1832 hospitalized patients with a diagnosis of Covid-19. The surveillance period among studies ranged from December 16, 2019 to February 23, 2020. The median patient age was 53 years and 53% were males. A total of 58.5% of patients presented with at least 1 comorbidity, most commonly hypertension (24.0%), cardiac disease (15.1%), and diabetes mellitus (14.4%). Fever and cough, reported in 84.8% and 61.7% of patients respectively, were the most common patient symptoms. The pooled mortality rate was 9.9% (95% confidence interval 6.1% to 14.5%). Funnel plot asymmetry was not observed and the meta-analysis results were not substantially influenced by any single study since the pooled mortality rate ranged from 8.9% to 11.1% following iterative removal of one study at a time. Substantial heterogeneity in the mortality rate was identified among studies (I² = 87%; P < .001). In a metaregression that included demographics, patient risk factors, and presenting symptoms, only a higher prevalence of diabetes mellitus was associated with a higher mortality rate (P = .03).

Conclusions: In a meta-analysis of hospitalized patients in China with a diagnosis of Covid-19, the mortality rate was 9.9% and a higher diabetes mellitus prevalence was independently associated with a worse prognosis. The independent influence of diabetes mellitus with Covid-19 mortality should be viewed as hypothesis-generating and warrants further study.

Abbreviations: CI = confidence interval, Covid-19 = coronavirus disease 2019, DM = diabetes mellitus, MERS-CoV = Middle East Respiratory Syndrome Coronavirus, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses, SARS = Severe Acute Respiratory Syndrome, SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2.

Keywords: case fatality rate, coronavirus, Covid-19, diabetes mellitus, infectious disease, meta-analysis, mortality, public health, systematic review

1. Introduction

The first human transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus responsible for Coronavirus Disease 2019 (Covid-19), was reported to occur in Wuhan, China on November 17, 2019.[1] On March 11, 2020, following identification of 118,000 Covid-19 cases and nearly 4,300 deaths in 114 countries, the World Health Organization recognized Covid-19 as a global pandemic.[2] The mortality rate associated with Covid-19 varies tremendously among countries with most studies originating from China. Several systematic reviews have reported mortality rates ranging from 4% to 13% in hospitalized patients with Covid-19 in China.[3–5] However, none of these reviews performed analyses to identify potential determinants of mortality rates in affected individuals. The purpose of this systematic review with meta-analysis was to determine the mortality rate of hospitalized patients with Covid-19 in China and to identify factors that may potentially influence this rate. We specifically focused the review to studies from China since most published papers on Covid-19 were derived from that
country and because the mortality rates associated with Covid-19 vary widely among geographic regions.\textsuperscript{6,7}

2. Methods

This systematic review was performed according to the PRISMA guidelines\textsuperscript{8} and the protocol was registered with the Research Registry (Review Registry UIN: reviewregistry861). Ethical approval and patient consent were not required because this is a systematic review and meta-analysis of previously published studies. The authors agree to make the raw data from this analysis available upon reasonable request.

We performed systematic searches of Medline, Embase, and the Cochrane Central Register of Controlled Trials for observational studies that reported the mortality rate of hospitalized patients in China with a confirmed diagnosis of Covid-19. The searches used the following keywords

2019-nCov, coronavirus, Covid-19, and SARS-CoV-2. We performed manual searches of the Directory of Open Access Journals, Google Scholar, and the reference lists of included papers and relevant meta-analyses. Finally, we searched medRxiv for unpublished manuscript preprints. No language restrictions were applied to the searches; manuscripts published in Chinese-language journals were translated to English by a medical translator. Eligible papers were published between December 1, 2019 and March 31, 2020.

Study selection was performed by 2 independent reviewers and discrepancies were resolved by consensus. Titles and abstracts were initially screened to exclude review articles, commentaries, non-research letters, studies with less than 20 patients, studies that exclusively enrolled special populations (e.g., children, pregnant women, elderly, critically ill patients, etc.), studies in which mortality was not reported, and clinical trials of experimental drugs for Covid-19. We additionally excluded papers derived from surveillance databases since hospital and out-patient records were not reported separately. Full-texts of the remaining articles were retrieved and reviewed.

Researchers independently extracted data from eligible studies using standardized data collection forms. For each study, we recorded metadata, patient characteristics (age, sex, comorbidities, presenting symptoms), study characteristics (sample size, number and location of participating hospitals, study design, Covid-19 diagnosis method, range of diagnosis dates), treatment data, risk of bias elements, and mortality rates. To account for multiple papers derived from the same primary study or subsamples of the primary study, we preferentially extracted data from the paper with the largest sample size and then supplemented missing data using other papers published from the same study as needed.

The primary outcome of this review was the mortality rate of hospitalized patients in China with a confirmed diagnosis of Covid-19. The mortality rate was calculated for each study and the overall pooled result was reported along with the 95% confidence interval (CI). Meta-analysis estimates were calculated from a random-effects restricted maximum likelihood model with inverse variance weighting to account for anticipated heterogeneity among studies. Because the mortality rate was expected to be proportionally near zero, we used the Freeman-Tukey double arcsine transformation for variance stabilization.\textsuperscript{9} The $I^2$ statistic was used to assess heterogeneity in the mortality rate among studies. Substantial heterogeneity was considered present when $I^2$ exceeded 50%. We performed prespecified metaregression analyses to explore potential sources of heterogeneity that included patient demographics, risk factors, and presenting symptoms. Variables that were included in the models were patient age, patient sex, risk factors (presence of at least one risk factor, hypertension, cardiac disease, diabetes mellitus [DM], respiratory disease), and presenting symptoms (fever, cough, dyspnea, myalgia, headache). Treatment regimens were largely individualized based on patient symptoms and, therefore, these data were reported descriptively and their associations with mortality were not analyzed due to the considerable risk of confounding. We evaluated the robustness of the meta-analysis conclusions with a one-study removed sensitivity analysis where the analysis was recalculated following iterative one-at-a-time removal of each study. Funnel plot asymmetry was evaluated by visual inspection only since statistical testing of asymmetry for prevalence outcomes in a single group yields biased results.\textsuperscript{10} The level of agreement between reviewers evaluating studies for inclusion, data abstraction, and quality assessment was assessed using simple and weighted kappa statistics. A two-sided $P$ value of less than .05 was considered statistically significant. Analyses were performed with Stata v16.1 (Stata Corp, College Station, TX, United States).

3. Results

The literature review included 950 records identified by systematic literature searches and 21 records identified by searches of the grey literature and articles published ahead-of-print from journal websites. Among the 971 papers, we retrieved the full text of 123 papers and ultimately included 16 papers involving 1832 hospitalized patients in China with a confirmed diagnosis of Covid-19 in the meta-analysis. The most common types of papers that were excluded from consideration were commentaries and non-research letters. A schematic of the study identification and selection process is shown in Figure 1.

Among the 16 observational studies,\textsuperscript{11–26} 12 were performed at a single center and 4 were multicenter studies. The sample sizes ranged widely across studies (median 90 patients; range 24 to 416 patients). Patients were prospectively enrolled in 1 study and retrospectively enrolled in the remainder of studies. The surveillance period among all studies ranged from December 16, 2019 to February 23, 2020 (Table 1). The median age of patients was 53 years and 53% were males. A total of 38.5% of patients presented with at least one comorbidity, most commonly hypertension (24.0%), cardiac disease (15.1%), and DM (14.4%). Fever and cough, reported in 84.8% and 61.7% of patients respectively, were the most commonly reported symptoms. Patient treatments were not standardized but were tailored to individual symptoms. Antivirals (90.8%), antibiotics (84.9%), and oxygen therapy (71.2%) were most commonly utilized (Fig. 2). The primary risks of bias pertaining to mortality rates were attributed to predominant retrospective patient enrollment and variability in patient age and risk factors among studies. Cohen’s inter-rater kappa statistic for inclusion agreement, abstraction, and quality assessment was 0.82, 0.86, and 0.80, respectively, indicative of excellent inter-rater agreement.

Among the 1832 patients, 251 died (crude mortality 13.7%). The mortality rate in individual studies ranged from 0% to 37.0%. In a random effects meta-analysis, the pooled mortality rate was 9.9% (95% CI 6.1%–14.5%) (Fig. 3). The mortality rate was minimally influenced by any single study and ranged from a low of 8.9% after removal of Zhou et al\textsuperscript{26} to a high of...
11.1% after removal of Xu et al 24 (Table 2). Substantial funnel plot asymmetry was not apparent by visual inspection (Fig. 4). Significant heterogeneity was identified in the mortality rate among studies ($I^2 = 87\%$; $P < .001$). We subsequently undertook a metaregression analysis to identify possible sources of study-to-study variability in this rate. Among the demographics, risk factors, and symptoms, the only variable that statistically significantly influenced the mortality rate was the prevalence of DM, where each 1% increase in DM prevalence was associated with a 1.5% absolute increase in the mortality rate ($P < .001$) (Table 3). A bubble plot that visually conveys the association between DM and mortality is provided in Figure 5.

### Table 1

| Study                   | No. patients | Male:female | Median age (yr) | No. hospitals | Hospital; location       | Study design | Diagnosis method | Diagnosis dates |
|-------------------------|--------------|-------------|-----------------|---------------|--------------------------|--------------|------------------|-----------------|
| Chen, L. et al 11      | 29           | 21:8        | 56              | 1             | Tongji Hospital; Wuhan   | R            | RT-PCR           | Jan 14-Jan 29   |
| Chen, N. et al 12      | 99           | 67:32       | 56              | 1             | Jin Yintan Hospital; Wuhan | R            | RT-PCR           | Jan 1-Jan 20    |
| Fu et al 13            | 36           | 16:20       | 45              | 1             | Third People’s Hospital; Kunming | R            | RT-PCR           | Jan 31-Feb 15   |
| Guo et al 14           | 187          | 91:96       | 59              | 1             | Seventh Hospital; Wuhan  | R            | RT-PCR           | Jan 23-Feb 23   |
| Huang et al 15         | 41           | 30:11       | 49              | 1             | Jin Yintan Hospital; Wuhan | P            | RT-PCR or NGS    | Dec 16-Jan 2    |
| Liu, K. et al 16       | 137          | 61:76       | 57              | 9             | Nine hospitals; Hubei province | R            | RT-PCR           | Dec 30-Jan 24   |
| Liu, L. et al 17       | 24           | 8:16        | 43              | 1             | Hunan Provincial People’s Hospital; Changsha | R            | RT-PCR           | Jan 8-Feb 8     |
| Peng et al 18          | 112          | 53:59       | 62              | 2             | Western Hospital & Union Medical College; Wuhan  | R            |                   |                 |
| Shi, H. et al 19       | 81           | 42:39       | 50              | 2             | Jin Yintan Hospital & Tongji Medical College; Wuhan | R            | RT-PCR or NGS    | Dec 20-Jan 23   |
| Shi, S. et al 20       | 416          | 205:211     | 64              | 1             | Renmin Hospital; Wuhan    | R            | RT-PCR           | Jan 20-Feb 10   |
| Tang et al 21          | 183          | 98:85       | 54              | 1             | Tongji Hospital; Wuhan    | R            | RT-PCR           | Jan 1-Feb 3     |
| Wang, D. et al 22      | 138          | 75:63       | 56              | 1             | Zhongnan Hospital; Wuhan  | R            | RT-PCR           | Jan 1-Jan 28    |
| Wang, Z. et al 23      | 69           | 32:37       | 42              | 1             | Union Hospital; Wuhan     | R            | RT-PCR           | Jan 16-Jan 29   |
| Xu et al 24            | 62           | 35:27       | 41              | 7             | Seven hospitals; Zhejiang province | R            | RT-PCR           | Jan 10-Jan 26   |
| Yuan et al 25          | 27           | 12:15       | 60              | 1             | Central Hospital; Wuhan    | R            | RT-PCR           | Jan 1-Jan 25    |
| Zhou et al 26          | 191          | 119:72      | 56              | 2             | Jin Yintan Hospital & Wuhan Pulmonary Hospital; Wuhan | R            | RT-PCR or NGS    | Dec 29-Jan 31   |

Note: Mean value reported.

NGS = next-generation sequencing, P = prospective, R = retrospective, RT-PCR = reverse transcription polymerase chain reaction.
4. Discussion

Covid-19 is an emerging infectious disease in which evidence related to disease transmission, susceptibility, and risk factors for mortality and morbidity are not well characterized and likely substantially influenced by multiple factors such as patient characteristics, geography, and adherence to social distancing recommendations. We undertook a systematic review and meta-analysis intended to characterize the mortality rate in a relatively homogenous group of patients, all of whom were hospitalized for Covid-19 in China. In 16 studies of 1832 patients with a confirmed diagnosis of Covid-19 between December 16, 2019 and February 23, 2020, the pooled mortality rate was 9.9%. This rate varied considerably among studies and the variability was partially explained by a significant relationship between DM prevalence and mortality rate. The association of Covid-19 treatment with mortality rate was unclear and meta-analysis on this topic was not attempted since treatments were individualized and directed at alleviating symptoms and associated manifestations of the disease. Overall, the results of this meta-analysis highlight the mortality burden of hospitalized patients in China receiving a diagnosis of Covid-19 and, for the first time in a meta-analysis, demonstrate a strong association of DM with patient mortality.

Several other meta-analyses have reported mortality rates with Covid-19 and a comparison of key findings and methodological considerations among these reviews is warranted. Our mortality estimate of 9.9% is comparable to the findings from prior reviews where mortality estimates ranged from 7.0%[3] to 13.9%[5] in hospitalized patients. The meta-analysis of Sun et al[4] reported a lower mortality rate of 4.3%, but 89% of the patients in that analysis were derived from a single paper of a government surveillance database where hospitalization status was not reported. It is likely that their mortality estimate of 4.3% reflected a mixed cohort of hospitalized and non-hospitalized patients. Further evidence of this discrepancy can be observed by an analysis where the mortality rate was higher when Covid-19 first emerged, but steadily decreased to approximately 4.3% as more cases were identified.[27] Therefore, it appears that the mortality rate of hospitalized patients in China is approximately 10%, but less than 5% overall when considering the mortality rate among all infected individuals regardless of hospitalization status.

Our systematic review is the first to evaluate the relationship of patient-related factors on mortality rates and, in this respect, this review provides new information. Among all variables related to demographics, comorbidities, and presenting symptoms, only the prevalence for DM was associated with mortality rates. While this finding was novel, it was not unexpected since individuals with DM have been shown to have a worse prognosis with other coronaviruses such as with the Severe Acute Respiratory Syndrome (SARS) outbreak in China in 2002[28,29] and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Middle East in 2012.[30] Additionally, Zhou and colleagues[26] reported that mortality risk due to Covid-19 was three-fold.
higher in diabetes versus nondiabetic patients. While the role of hyperglycemia in the development and prognosis of Covid-19 remains speculative, potential mechanisms by which susceptibility for Covid-19 might be increased in patients with DM include higher affinity cellular binding for more efficient virus entry, inhibition of viral clearance, impaired T-cell function. Chronic hyperglycemia and association in inflammation may also contribute to an abnormal and ineffective immune response, thereby increasing susceptibility to hyperinflammation and cytokine storm syndrome. Diabetics with viral infection also have a greater risk of diabetic ketoacidosis, which inhibits the ability to mitigate sepsis, a major contributor to death among persons with Covid-19. Others have suggested that poor in-hospital glycemic control during hospital quarantine for Covid-19 may further contribute to mortality risk, potentially owing to prioritization of life-saving treatments, limited medical personnel, unavailability of personalized diets, and limited physical activity. Thus, the findings of this meta-analysis inform working hypotheses that individuals with hyperglycemia may have a worse prognosis with Covid-19, improved glycemic control during hospitalization may improve prognosis, and individuals with DM represent a vulnerable population whose propensity for or severity of infection may be blunted with vaccination. The accumulating

---

**Table 2**

| Study                  | Mortality rate (%) | 95% CI   |
|------------------------|-------------------|----------|
| Overall                | 9.9               | 6.1, 14.5|
| Chen, L. et al[11]     | 10.1              | 6.1, 14.9|
| Chen, N. et al[22]     | 9.8               | 5.7, 14.8|
| Fu et al[23]           | 10.9              | 6.9, 15.6|
| Guo et al[14]          | 9.1               | 5.3, 13.7|
| Huang et al[15]        | 9.7               | 5.7, 14.4|
| Liu, K. et al[16]      | 9.8               | 5.7, 14.8|
| Liu, L. et al[17]      | 10.7              | 6.7, 15.5|
| Peng et al[18]         | 9.5               | 5.5, 14.4|
| Shi, H. et al[19]      | 10.4              | 6.4, 15.3|
| Shi, S. et al[20]      | 9.6               | 5.3, 14.9|
| Tang et al[21]         | 9.9               | 5.6, 14.8|
| Wang, D. et al[22]     | 10.4              | 6.4, 15.3|
| Wang, Z. et al[23]     | 10.1              | 6.0, 15.0|
| Xu et al[24]           | 11.1              | 7.2, 15.6|
| Yuan et al[25]         | 9.0               | 5.3, 13.4|
| Zhou et al[26]         | 8.9               | 5.4, 13.0|

* Values represent mortality rate in meta-analysis following removal of indicated study.
CI = confidence interval.
evidence regarding increased Covid-19 risk among diabetics prompted the American Association of Clinical Endocrinologists to issue a position statement specifically related to Covid-19 and diabetics where additional recommendations are provided.\textsuperscript{[33]}

The main strengths of this review were prospectively defined methodology, adherence to PRISMA guidelines, inclusion of patients from a single geographic region, and robust conclusions that were unchanged in sensitivity analyses. There were also several important limitations that warrant further discussion. First, definitive causal relationships cannot be established from metaregression findings and, therefore, the observed association of DM with mortality should be considered as hypothesis-generating for future studies. Second, it is plausible that other factors were associated with mortality but were not detected due to aggregation bias whereby real associations observed at the patient level (e.g., age of each patient) may not agree with those observed at the study level (e.g., mean patient age in each study) when data are pooled in a meta-analysis.\textsuperscript{[34]} Third, the generalizability of these results to other geographic regions is unclear owing to factors such as differences in healthcare resources, population age and health, and adherence to social distancing recommendations. Fourth, we excluded studies that only enrolled highly selected populations such as pregnant women and critically ill patients. Although these selection criteria were implemented to minimize selection bias, we were unable to derive conclusions regarding Covid-19 mortality in special populations from this analysis. Finally, most patients with Covid-19 in this review represented the initial cluster prior to declaration of a worldwide pandemic and surveillance data suggest that the mortality rate appeared to plateau in China after only a few months following the initial outbreak. The factors that led to this decrease are unknown and there are undoubtedly additional factors that influenced mortality rates but were not amenable to formal analysis such as unmeasured or rarely reported comorbidities (e.g., chronic kidney disease), variability in treatments that likely differed by hospital and disease stage, and hospital preparedness/response status.

5. Conclusion

In a meta-analysis of hospitalized patients in China with a diagnosis of Covid-19, the mortality rate was 9.9% and a higher diabetes mellitus prevalence was independently associated with a worse prognosis. The independent influence of diabetes mellitus with Covid-19 mortality should be viewed as hypothesis-generating and warrants further study.

Acknowledgments

We thank David Fay, PhD for assistance with literature review and Li Xiu Ying for providing Chinese-to-English translation.

### Table 3

| Variable                        | Studies | Regression coefficient\textsuperscript{*} | 95% CI     | P value |
|---------------------------------|---------|--------------------------------------------|------------|---------|
| Diabetes mellitus (%)           | 14      | 1.5%                                       | 0.2, 2.8   | .03     |
| Age, yr                         | 16      | 0.6%                                       | -0.2, 1.4  | .14     |
| Fever (%)                       | 14      | 0.3%                                       | -0.3, 0.9  | .31     |
| Headache (%)                    | 11      | -0.4%                                      | -1.3, 0.5  | .33     |
| Any pre-existing comorbidity (%)| 15      | 0.1%                                       | -0.2, 0.5  | .42     |
| Hypertension (%)                | 13      | 0.1%                                       | -0.2, 0.5  | .44     |
| Respiratory disease (%)         | 11      | -1.0%                                      | -3.9, 1.8  | .44     |
| Myalgia (%)                     | 14      | -0.1%                                      | -0.4, 0.2  | .51     |
| Cough (%)                       | 14      | 0.1%                                       | -0.2, 0.5  | .51     |
| Male sex (%)                    | 16      | 0.2%                                       | -0.5, 0.8  | .61     |
| Dyspnea (%)                     | 13      | 0.1%                                       | -0.4, 0.6  | .64     |
| Cardiac disease (%)             | 11      | -0.1%                                      | -0.2, 0.4  | .70     |

\textsuperscript{*}Indicates absolute increase in mortality rate for each unit of change in the independent variable. For example, each 1% increase in the prevalence of diabetes mellitus among studies was associated with a 1.5% increase in mortality.
CI = confidence interval.

---

**Figure 4.** Funnel plot of mortality in hospitalized patients in China diagnosed with Covid-19. Funnel plot asymmetry due to small-study effects was not apparent by visual inspection.

**Figure 5.** Metaregression of the association between diabetes mellitus and mortality in hospitalized patients in China diagnosed with Covid-19. Open circles represent values of individual studies where circle size is proportional to the study weight in the random-effects model. The red line represents the regression line of best fit. \textit{P} = .03.
services. The authors had no writing assistance in the preparation of this manuscript.

Author contributions
Conceptualization: Larry E. Miller.
Data curation: Larry E. Miller, Ruemon Bhattacharyya, Anna L Miller.
Formal analysis: Larry E. Miller.
Investigation: Larry E. Miller, Ruemon Bhattacharyya, Anna L Miller.
Methodology: Larry E. Miller, Ruemon Bhattacharyya, Anna L Miller.
Project administration: Larry E. Miller, Ruemon Bhattacharyya, Anna L Miller.
Resources: Larry E. Miller, Ruemon Bhattacharyya, Anna L Miller.
Supervision: Anna L Miller.
Validation: Anna L Miller.
Visualization: Larry E. Miller, Ruemon Bhattacharyya.
Writing – original draft: Larry E. Miller.
Writing – review & editing: Ruemon Bhattacharyya, Anna L Miller.

References
[1] South China Morning Post. Coronavirus: China’s first confirmed Covid-19 case traced back to November 17. 2020. https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back. Accessed March 19, 2020.
[2] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19, 11 March, 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11—march-2020. Accessed March 19, 2020.
[3] Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:777–83.
[4] Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol 2020;92:612–7.
[5] Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;31:101623.
[6] Center for Infectious Disease Research and Policy. COVID-19 maps & visuals. 2020. http://www.cidrap.umn.edu/covid-19/maps-visuals. Accessed March 19, 2020.
[7] Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Global map. 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/world-map.html. Accessed March 17, 2020.
[8] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65–94.
[9] Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950;21:607–11.
[10] Hunter JP, Sartazis A, Sutton AJ, et al. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol 2004;67:597–603.
[11] Chen L, Liu HG, Liu W, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He Hu Xi Za Zhi 2020;43:E005.
[12] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
[13] Fu H, Li H, Tang X, et al. Analysis on the clinical characteristics of 36 cases of novel coronavirus pneumonia in Kunming, 2020. https://www.medrxiv.org/content/10.1101/2020.02.18.20029173v1.full.pdf. Accessed March 15, 2020.
[14] Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811–8.
[15] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
[16] Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133:1025–31.
[17] Liu L, Zhang D, Tang S, et al. The epidemiological and clinical characteristics of 2019 Novel coronavirus infection in Changsha, China, 2020. http://dx.doi.org/10.2139/asm.3537093. Accessed March 15, 2020.
[18] Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020;48:E004.
[19] Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:423–34.
[20] Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–10.
[21] Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.
[22] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
[23] Wang C, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020;71:769–77.
[24] Xu XW, Wu XX, Jiang XG, et al. Clinical, laboratory and imaging features of COVID-19 pneumonia in Wuhan, China: a descriptive study. JAMA Cardiol 2020;5:802–10.
[25] Yuan M, Yin W, Tao Z, et al. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 2020;15:e0230548.
[26] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[27] Worldometer. China Coronavirus Cases. https://www.worldometers.info/coronavirus/country/china/. Accessed April 1, 2020.
[28] Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23:623–8.
[29] Zhang L, Chen N, Yuan M, et al. Clinical features and outcomes of severe acute respiratory syndrome: a retrospective cohort study in Wuhan, China. JAMA 2020;323:1054–62.
[30] Nassar MS, Bakreheba MA, Meo SA, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci 2018;22:4956–61.
[31] Munyapapa R, Gubbi S. COVID-19 pandemic, corona viruses, and diabetes mellitus. Am J Endocrinol Endocrinol Metab 2020;318:E736–41.
[32] Zhou H, Tan J. Diabetes patients with COVID-19 need better care. JAMA 2020;323:1061–9.
[33] Cooper H, Patall EA. The relative benefits of meta-analysis conducted with individual participant data versus aggregated data. Psychol Methods 2009;14:165–76.